Aurobindo Pharma Q1 net profit declines 2% to Rs 770 crore

By: |
August 12, 2021 9:46 PM

The company had posted a net profit of Rs 783.16 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a regulatory filing.

Drug firm Aurobindo Pharma earning, Aurobindo Pharma Q4 profit share, revenue from operations, transfer of all equity sharesThe Board has declared an interim dividend of Rs 1.50 per share, Aurobindo Pharma said

Drug firm Aurobindo Pharma on Thursday reported a 1.68 per cent decline in its consolidated net profit to Rs 769.97 crore for the quarter ended on June 30, 2021, mainly on account of reduction in expenses.

The company had posted a net profit of Rs 783.16 crore for the corresponding period of the previous fiscal, Aurobindo Pharma said in a regulatory filing.

Consolidated total revenue from operations of the company stood at Rs 5,701.98 crore for the quarter under consideration. It was Rs 5,924.78 crore for the same period a year ago, it added.

“The quarter’s performance reflected the resilience in our operations amidst the current challenging times. We remain focused on ensuring business continuity on the operations front and to resolve regulatory issues in some of our facilities,” Aurobindo Pharma MD N Govindarajan said.

The company’s business is well prepared to navigate the journey towards profitable growth and it looks forward to execute on its key growth pillars, he added.

The expenses of the company were at Rs 4,785.17 crore for the quarter ended June 2021 against Rs 4,944.02 crore for the corresponding period of the previous fiscal.

Total tax expenses of the company stood at Rs 247.74 crore for the quarter ended June this year against Rs 301.19 crore for the same period a year ago, the filing said.

The Board has declared an interim dividend of Rs 1.50 per share, Aurobindo Pharma said.

The company has entered into definitive agreements under which it will subscribe to fresh equity shares in Cronus Pharma Specialities India Pvt Ltd, subject to closing conditions, amounting to Rs 420 crore. Subsequent to this investment, the company will own 51 per cent of the equity share capital of Cronus, it added.

Shares of Aurobindo Pharma closed at Rs 825.70 on BSE, down 3.64 per cent from the previous close.

 

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.

Next Stories
1Shapoorji Pallonji Group sells Eureka Forbes to Advent in Rs 4,400-crore deal
2Spectrum charges: Dept of Telecommunications to abolish 3% floor rate
3Low code app platforms: App development made fast & simple